Anti-IL-12 antibody prevents the development and progression of multiple sclerosis-like relapsing-remitting demyelinating disease in NOD mice inducedwith myelin oligodendrocyte glycoprotein peptide
M. Ichikawa et al., Anti-IL-12 antibody prevents the development and progression of multiple sclerosis-like relapsing-remitting demyelinating disease in NOD mice inducedwith myelin oligodendrocyte glycoprotein peptide, J NEUROIMM, 102(1), 2000, pp. 56-66
Treatment with monoclonal anti-IL-12 antibody injected on day 0, 7 and 10 a
fter immunization with myelin oligodendrocyte glycoprotein (MOG) peptide 35
-55 in NOD mice resulted in significant suppression of the development and
the severity of the chronic relapsing-remitting experimental autoimmune enc
ephalomyelitis (EAE) both clinically and histologically. The spleen cells f
rom anti-IL-12 antibody treated mice displayed markedly inhibited MOG(35-55
) specific proliferation and IFN-gamma production. MOG(35-55) specific anti
body production was enhanced by anti-IL-12 antibody treatment. These result
s suggest that IL-12 is critically involved in the pathogenesis of MOG-indu
ced EAE and that antibody to IL-12 could be an effective therapeutic agent
in the clinical treatment of autoimmune demyelinating diseases such as mult
iple sclerosis (MS). (C) 2000 Elsevier Science B.V. All rights reserved.